---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-222746"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2026-05-14T11:02:34+00:00"
generated_at: "2026-05-14T11:07:51.306255+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Larimar plans rolling BLA for nomlabofusp in June 2026; Q1 net loss $29.6M

## Summary
- Net loss Q1 2026 $29.6M ($0.31/sh) vs Q1 2025 $29.3M ($0.46/sh). Cash $200.4M.
- Intends to initiate rolling BLA seeking accelerated approval June 2026; CMC module H2 2026.
- Topline open-label study data expected Q2 2026; Phase 3 first patient dose mid-2026.
- Breakthrough Therapy Designation granted Feb 2026. Skin frataxin as surrogate endpoint supported by published data.
- Feb 2026 $115M public offering extended cash runway into Q2 2027.

## SEC filing metadata
- accession: 0001193125-26-222746
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2026-05-14T11:02:34+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000119312526222746/0001193125-26-222746-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000119312526222746/lrmr-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-222746
- JSON: https://secwatch.observer/filing/0001193125-26-222746.json
- Plain text: https://secwatch.observer/filing/0001193125-26-222746.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.